2023 Fiscal Year Annual Research Report
Assessment of PilVax nasal vaccine for preventing influenza virus infection
| Project/Area Number |
22KF0065
|
|---|
| Allocation Type | Multi-year Fund |
|---|
| Research Institution | Chiba University |
|---|
Principal Investigator |
藤橋 浩太郎 千葉大学, 医学部附属病院, 特任教授 (50820354)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
TSAI JIA-YUN 千葉大学, 医学部附属病院, 外国人特別研究員
|
|---|
| Project Period (FY) |
2023-03-08 – 2024-03-31
|
| Keywords | Vaccine / influenza virus / IgA / Protection |
|---|
| Outline of Annual Research Achievements |
Age-matched female BALB/c mice were immunized with of PilVax vaccines (1 X 10^8 CFU, in a volume of 10 ul) presenting two tandem copies (M2e-M2e-PilVax) of the M2e peptide. The vaccines were administered on 3 consecutive days with additional 3 boosters given 2 weeks apart, for a total of 12 doses. One week after the final immunization (day 51 or 49), serum, bronchoalveolar lavage (BAL) nasal washes (NWs) and saliva were collected and subjected to M2e-specific ELISAs. Significantly increased levels of M2e-specific serum IgG and mucosal IgA antibody responses were noted. When vaccinated mice were challenged with influenza virus (H1N1, e.g., A/California) in order to confirm protective immunity, nasal PilVax immunized mice showed complete protection from the virus challenge.
|
